GLP-1–based therapies and limb outcomes in peripheral artery disease (PAD): a systematic review and meta-analysis of real-world studies
Pooled result · MALEResult — go to the resultHazard ratio 0.59 95% CI 0.39–0.90Authors' conclusion
In real-world PAD populations, GLP-1-based therapies are associated with meaningful reductions in both limb and cardiovascular outcomes. These findings support a vascular protective profile, particularly for stroke and MACE in more homogeneous populations such as patients with diabetes.
Study context
- Population
- Adults with PAD in comparative real-world studies6 studies · >240,000 patients
- Comparison
- GLP-1-based therapies vs comparators
- Outcome
- Major adverse limb events (MALE), MACE and mortality
Methodological detailsSearch of MEDLINE, Embase, Cochrane CENTRAL, Scopus and grey literature
- Search of MEDLINE, Embase, Cochrane CENTRAL, Scopus and grey literature
Pooled result
MALE
Hazard ratio
0.59
95% CI 0.39–0.90
GLP-1-based therapies (GLP-1RAs and tirzepatide)vs comparators
HR 0.59 (95% CI 0.39–0.90)
As reported in the abstract
Further pooled results
Major adverse cardiovascular events (MACE)
- Significant reduction in MACE, HR
- 0.67 (0.53-0.85) (95% CI)
- Greater consistency in diabetic populations
Stroke
- Stroke significantly reduced, HR
- 0.75 (0.63-0.89) (95% CI)
- Consistent effects across studies
MI and all-cause mortality
- MI and all-cause mortality also significantly reduced, with greater variability in effect magnitude
Original publication
GLP-1–based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies. Diabetes Res Clin Pract. Published 19 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →